In addition, the PFGE patterns were analyzed using Bionumerics version 5.10 (Applied Maths, Sint-Martens -Latem, Belgium) for comparison with other KPC-2-producing strains previously identified in Brazil. 3 Multilocus sequence typing (MLST) of K. pneumoniae was performed as described previously. 14 Experimentally determined DNA sequences were uploaded into the MLST database (http://www.pasteur.fr/recherche/genopole/PF8/mlst/ Kpneumoniae.html), and allelic numbers and sequence types (ST) were obtained.
K. pneumoniae isolates were more frequently collected from bloodstream infections (n = 4; 57.1%) ( Table 1) . Amikacin, polymyxin B, and tigecycline showed the highest susceptibility rates (100%) against the isolates studied, followed by meropenem (57.1%), imipenem (14.3%), and cefepime (14.3%). In contrast, 100% of the isolates were resistant to ertapenem, ceftriaxone, and aztreonam. Resistance to ceftazidime, cefoxitin, and ciprofloxacin was observed in six isolates (87.5%). All isolates showed positive MHT results and were found to carry the bla KPC-2 gene. Two PFGE patterns, A and B, were found among the seven KPC-KPN; the genotype A was the most frequent (n = 5; 71.3%). Besides the presence of bla KPC-2 , genotype A (ST 437) isolates also carried bla TEM-1 , bla OXA-1 , bla CTX-M-15 , and bla SHV-11 , while genotype B (ST 70) carried only bla . Using the dendrogram, a similarity of nearly 79.3% was detected between genotype A and B. The similarity of the KPC-producing isolates evaluated in this study compared to those previously isolated in Recife 3 was 74.5%.
For the first time, K. pneumoniae isolates resistant to ertapenem were detected in the Hospital Lauro Wanderley, which were further confirmed as KPC producers. Among the isolates studied, one (335) showed susceptibility to meropenem and imipenem, whereas three isolates (337, 339, and 341) were only susceptible to meropenem, according to the CLSI breakpoints. 10 The discrepancy observed in the susceptible categories to carbapenems may be attributed to production of carbapenemases like KPC. The co-production of KPC with other beta-lactamases, such as TEM-1, OXA-1, SHV-11, SHV-27 and CTX-M-15, was observed among KPC-KPN isolates. These findings are in agreement with previous Brazilian reports which showed that KPC-KPN isolates also possessed the bla CTX-M , bla TEM , and bla SHV genes. 3, 5, 15 Although CTX-M-2 is a widespread variant in South America, the isolates evaluated carried bla CTX-M-15 , a frequently found worldwide CTX-M-type.
Additionally, according to the authors' knowledge, this is the first description of co-production of KPC-2 and OXA-1 in Brazilian isolates. ST 437, the most prevalent among the KPC-KPN evaluated, is a ST related to the clonal complex 258, which is widely disseminated among KPC-KPN in Brazil, and associated with the dissemination of KPC worldwide.
Since the therapeutic options are limited and the appropriate empirical antimicrobial treatment is of crucial importance to patient outcome, 16 we suggest that the clinical laboratory perform accurate susceptibility testing for KPC producers, including the determination of MICs for tigecycline, aminoglycosides, polymyxins, and carbapenems, since KPC-KPN isolates with low carbapenems MICs and/or isolates with discrepancy for susceptible category among carbapenems tested were observed. In addition, regional surveillance studies that monitor the dissemination of ESBL and carbapenemase enzymes are crucial, since most of these genes are located on mobile genetic elements, which are easily transferred to other bacteria species. Because four of the five isolates were clonally related, suggesting a patient-to-patient transmission, implementation of infection control measures is necessary to restrain the dissemination of resistant genes.
